Osmotica Pharmaceuticals plc logo
Osmotica Pharmaceuticals plc OSMT

Osmotica Pharmaceuticals plc Net Income | OSMT

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Osmotica Pharmaceuticals plc

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-79.6 M -271 M -109 M -45.2 M -41.8 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-41.8 M -271 M -109 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
RAPT Therapeutics RAPT Therapeutics
RAPT
-130 M - - $ 2.36 B usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
479 M $ 144.21 0.72 % $ 14.3 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
-24 M $ 25.1 0.16 % $ 1.2 T franceFrance
NuCana plc NuCana plc
NCNA
-29.4 M $ 1.06 2.75 % $ 11.9 B britainBritain
Minerva Neurosciences Minerva Neurosciences
NERV
-293 M $ 3.32 1.22 % $ 28.1 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
-164 M $ 42.22 2.2 % $ 712 M usaUSA
Nkarta Nkarta
NKTX
-104 M $ 2.53 0.59 % $ 187 M usaUSA
NanoViricides NanoViricides
NNVC
-8.22 M $ 1.45 13.28 % $ 29.3 M usaUSA
Nurix Therapeutics Nurix Therapeutics
NRIX
-264 M $ 22.88 0.09 % $ 1.98 B usaUSA
Nuvation Bio Nuvation Bio
NUVB
-205 M $ 4.95 1.07 % $ 1.69 B usaUSA
Novavax Novavax
NVAX
440 M $ 12.56 20.08 % $ 2.03 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
102 B $ 37.54 0.59 % $ 167 B danmarkDanmark
Novartis AG Novartis AG
NVS
14 B $ 140.93 0.01 % $ 273 B schweizSchweiz
NextCure NextCure
NXTC
-55.8 M $ 5.05 0.59 % $ 14.4 M usaUSA
Ocugen Ocugen
OCGN
-68 M $ 1.04 1.96 % $ 325 M usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
-266 M $ 7.25 4.17 % $ 1.36 B usaUSA
Oragenics Oragenics
OGEN
-984 K $ 0.49 1.25 % $ 1.06 M usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
-162 M $ 8.25 0.3 % $ 718 M usaUSA
Omeros Corporation Omeros Corporation
OMER
-3.35 M $ 18.9 1.56 % $ 1.2 B usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
-31.7 M $ 0.6 1.21 % $ 57.5 M canadaCanada
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
-129 M $ 12.49 2.34 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
64 M $ 4.55 1.34 % $ 188 M israelIsrael
Outlook Therapeutics Outlook Therapeutics
OTLK
-62.4 M $ 0.6 0.42 % $ 20.9 M usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
-17.4 M $ 2.34 0.21 % $ 305 M usaUSA
Passage Bio Passage Bio
PASG
-7.56 M $ 4.09 0.73 % $ 13.1 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
31.1 M $ 9.67 1.68 % $ 484 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
-13.6 M $ 1.49 0.62 % $ 1.95 M usaUSA
Vaxcyte Vaxcyte
PCVX
-767 K $ 73.82 30.7 % $ 10 B usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
-7.56 M $ 1.2 60.32 % $ 55.7 M usaUSA
Pfizer Pfizer
PFE
7.77 B $ 27.41 0.02 % $ 156 B usaUSA
Precigen Precigen
PGEN
-251 M $ 7.74 4.02 % $ 2.42 B usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
33 M $ 9.8 0.51 % $ 6.75 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
-221 K $ 6.7 1.77 % $ 489 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
-8.7 M $ 0.99 0.6 % $ 5.92 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
149 M $ 1.03 0.48 % $ 63.2 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
-6.6 M $ 2.71 0.37 % $ 213 M israelIsrael
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
-77.7 M $ 1.78 2.29 % $ 93.5 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
-303 M $ 283.56 3.0 % $ 6.38 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
-5.02 M $ 0.88 0.04 % $ 570 K israelIsrael
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
-99.5 M $ 3.77 2.72 % $ 290 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
-42.2 M $ 1.67 2.14 % $ 176 M niderlandNiderland
Prothena Corporation plc Prothena Corporation plc
PRTA
-244 M $ 8.27 0.35 % $ 445 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
683 M $ 63.65 0.3 % $ 5.06 B usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
-130 M $ 140.63 0.41 % $ 8.94 B usaUSA
Pulmatrix Pulmatrix
PULM
-1.17 M $ 1.48 0.64 % $ 5.41 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
-34.2 M $ 5.2 0.19 % $ 85 M israelIsrael
Repare Therapeutics Repare Therapeutics
RPTX
-84.7 M - - $ 112 M canadaCanada
uniQure N.V. uniQure N.V.
QURE
-199 M $ 22.8 0.39 % $ 1.31 B niderlandNiderland
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
-223 M $ 2.61 1.95 % $ 290 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
-353 M $ 24.74 1.23 % $ 2.66 B usaUSA